(NYSE: CRL) Charles River Laboratories International's forecast annual revenue growth rate of 3.04% is not forecast to beat the US Diagnostics & Research industry's average forecast revenue growth rate of 8.53%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.44%.
Charles River Laboratories International's revenue in 2026 is $4,015,382,000.On average, 19 Wall Street analysts forecast CRL's revenue for 2026 to be $201,833,980,000, with the lowest CRL revenue forecast at $194,548,265,600, and the highest CRL revenue forecast at $211,679,540,000. On average, 19 Wall Street analysts forecast CRL's revenue for 2027 to be $207,790,543,800, with the lowest CRL revenue forecast at $188,296,335,000, and the highest CRL revenue forecast at $224,281,856,800.
In 2028, CRL is forecast to generate $216,897,686,800 in revenue, with the lowest revenue forecast at $195,138,999,200 and the highest revenue forecast at $240,034,752,800.